Background and Purpose-Whether maximal treatment should be offered to elderly patients suffering from poor-grade aneurysmal subarachnoid hemorrhage (aSAH) is controversial. The survival of patients in this subgroup beyond the usual outcome measurements 6 to 12 months after aSAH is unclear. The purpose of this study is to provide survival and outcome data to support clinicians making decisions on treatment for this subgroup of patients. Methods-We performed a retrospective analysis of the Bernese SAH database for poor-grade (World Federation of Neurosurgical Societies grade IV and V) elderly patients (age ≥60 years) suffering from aSAH admitted to our institution from 2005 to 2017. Patients were divided into 3 age groups (60-69, 70-79, and 80-90 years). Survival analysis was performed to estimate mean survival and hazard ratios for death. Binary logarithmic regression was used to estimate the odds ratio for favorable (modified Rankin Scale score of 0-3) and unfavorable (modified Rankin Scale score of 4-6) outcome. Results-Increasing age was associated with an increasing risk of death after aSAH. The hazard ratio increased by 6% per year of age (P<0.001; hazard ratio, 1.06; 95% CI, 1.03-1.09) and 76% per decade (P<0.001; hazard ratio, 1.76; 95% CI, 1.35-2.29). Mean survival was 56.3±8 months (patients aged 60-69 years), 31.6±7.6 months (70-79 years), and 7.6±5.8 months (80-90 years). Unfavorable outcomes 6 to 12 months after aSAH were strongly related to older age. The odds ratio increased by 11% per year of age (P<0.001; odds ratio, 1.11; 95% CI, 1.05-1.18) and 192% per decade (P<0.001; odds ratio, 2.92; 95% CI, 1.63-5.26). Conclusions-Risk for death and unfavorable outcome increases markedly with older age in elderly patients with poorgrade aSAH. Despite a high initial mortality, treatment resulted in a reasonable proportion of favorable outcomes up to 79 years of age and only a small number of patients who were moderately or severely disabled 6 to 12 months after aSAH. Mean survival and proportion of favorable outcomes decreased markedly in patients older than 80 years. (Stroke.
T reatment of elderly patients (≥60 years) suffering from poor-grade aneurysmal subarachnoid hemorrhage (aSAH) remains a clinical challenge. Longer life expectancies 1 are leading to aging populations and incidence rates of aSAH increase with age. 2, 3 The management of elderly aSAH patients has changed substantially over the past 50 years from a mainly conservative approach 4 to early treatment comprising microsurgical clipping, endovascular treatment, and neurointensive care. 5, 6 As a result, clinical practice has also changed and more elderly aSAH patients are being referred to neurosurgical centers. Recent studies considering all grades of severity have reported reasonable outcomes after treatment of elderly aSAH patients. [5] [6] [7] [8] [9] [10] Whereas it is accepted clinical practice to offer maximum treatment to good-grade patients, decisions on treatment for elderly patients with poor-grade aSAH can be challenging. The literature reporting outcomes for elderly patients with poorgrade aSAH is scarce and survival beyond the usual outcome measurements (6-12 months after aSAH) remains unclear. Most of the available studies looked at elderly aSAH patients in general and included only small subgroups of poor-grade cases [5] [6] [7] [8] [10] [11] [12] [13] [14] [15] or provided outcome data at discharge but not during follow-up. 9 To fill this data gap, the present study specifically addresses the subgroup of elderly patients with poor-grade aSAH (age ≥60 years/World Federation of Neurosurgical Societies [WFNS] grade IV and V). The aim of the study was to analyze outcome and additional survival data to provide evidence that would help in making informed and reasonable treatment decisions for this challenging subgroup of aSAH patients.
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Methods

Data Collection
Data collection was approved by the local institutional ethics committee. The data that support the findings of this study are available from the corresponding author on reasonable request. 
Results
Population
From January 2005 to January 2017, 982 patients diagnosed with nontraumatic SAH were referred to our institution, 377 of whom were older than 60 years. In 7 cases, medical records were insufficient for further analysis. Two hundred fifteen patients with good-grade SAH (WFNS I-III) were excluded, as well as 9 patients with nonaneurysmatic SAH, leaving 146 patients who could be included in the study ( Figure I in the online-only Data Supplement). Seventy-two patients were aged 60 to 69 years, 54 patients 70 to 79 years, and 20 patients 80 to 90 years. One hundred eight (74%) patients were female. WFNS grades IV and V (P=0.79) and mean admission Glasgow coma scale (P=0.52) were evenly distributed between the age groups. Older patients tended to have a higher occurrence rate of ICH (P=0.08). The mean ICH volume (a×b×c/2) 17 between age groups ranged from 23.4 to 34.8 cm 3 (P=0.6). Discharge from the neurosurgical center was categorized according to destination: home, rehabilitation, external hospital, or death, and differed significantly between age groups (P=0.047). Differences between age groups in the mean duration of hospitalization at the neurosurgical center (P<0.001) and the decision not to perform microsurgical or endovascular treatment of an aneurysm were also significant (P=0.001). The frequency of withdrawal of care tended to be higher in older age groups, but this trend was not statistically significant (P=0.052). For details of the baseline characteristics see Table 1 .
Survival Analysis
One hundred forty-five of 146 patients were included in the survival analysis, amounting to 282 follow-up years with a mean follow-up of 23.51±38.14 months. One patient left the country and was therefore excluded from the analysis. During the investigation period, 104 of 145 patients were censored for death (71.7%). Mean survival after aSAH was 56.3±8 months for patients aged 60 to 69 years, 31.6±7.6 months for patients aged 70 to 79 years, and 7.6±5.8 months for those aged 80 to 90 years (log rank: P<0.001). The Kaplan-Meier curve of the survival function is displayed in Figure 1 .
The univariable Cox proportional hazard regression model was used to determine the HR of death after aSAH compared with patients aged 60 to 69 years: 70 to 79-year-olds had a 55% higher HR (P=0.046; HR, 1.55; 95% CI, 1.01-2.38) and 80 to 90-year-olds a 240% higher HR (P<0.001; HR, 3.4; 95% CI, 1.97-5.87) than the reference group. If age was analyzed as a continuous variable, the HR increased by 6% with every year of age (P<0.001; HR, 1.06; 95% CI, 1.03-1.09) and by 76% per decade (P<0.001; HR, 1.76; 95% CI, 1.35-2.29). Patients graded WFNS V had a 154% higher HR than WFNS IV patients (P<0.001; HR, 2.54; 95% CI, 1.56-4.13). The presence of ICH was associated with a 66% higher HR (P=0.02; HR, 1.66; 95% CI, 1.08-2.56; Table 2 ).
An additional multivariable Cox proportional hazards regression model, including age groups, WFNS grade, and ICH showed a 285% higher HR of death for patients aged 80 to 90 years compared with those aged 60 to 69 years (P<0.001; HR, 3.85; 95% CI, 2.16-6.86). The results for the patients in the 70 to 79-year age group were close to a statistically significant level (P=0.051; Table 2 ).
Outcome
Information on outcome was available for 145 patients at discharge and for 141 patients 6 to 12 months after aSAH. The distribution of mRS (Figure 2A and 2B) was significantly different when comparing age groups at discharge (P=0.003) and 6 to 12 months after aSAH (P=0.001).
A favorable outcome at discharge (mRS score of 0-3) was achieved by 26.8% of 60 to 69-year-olds, 9.3% of 70 to 79-year-olds, and 0% of 80 to 90-year-olds. Favorable outcomes 6 to 12 months after aSAH were reported for 41.4% of patients aged 60 to 69 years, 17.6% of those aged 70 to 79 years, and 10% of patients aged 80 to 90 years. Pearson χ 2 testing showed a significant association between age group and outcome at discharge (P=0.003) as well as with outcome 6 to 12 months after aSAH (P=0.002; Table 3 ).
Binary logarithmic regression was used to estimate the OR for an unfavorable outcome compared with patients who were 60 to 69 years old at discharge and 6 to 12 months after aSAH: at discharge, the OR increased by 234% in patients aged 70 to 79 years (P=0.021; OR, 3.34; 95% CI, 1.2-9.3). The result for patients who were 80 to 90 years old was not significant. The estimation of OR about the outcome in the 80-to 90-year-old patient group at discharge is difficult because no favorable outcomes were observed. This leads to large uncertainty, as reflected by the wide CI, despite the high OR. When age was analyzed as a continuous variable, the OR increased by 11% per year of age (P=0.004; OR, 
Discussion
In this study involving elderly patients (≥60 years) with poor-grade aSAH (WFNS IV and V), the survival analysis showed that increasing age was associated with an increasing risk of death after aSAH. The HR increased by 6% per year of age and by 76% per decade. Mean survival in all of the age groups examined decreased significantly. Furthermore, unfavorable outcomes were associated with older age. The OR for an unfavorable outcome 6 to 12 months after aSAH increased by 11% per additional year of age and by 192% per decade of age. 
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The results of this study offer valuable information for clinicians to aid them in deciding whether or not maximal treatment should be offered to elderly patients with poor-grade aSAH. To our knowledge, this is the largest series reporting survival and outcome in this particular subgroup. Furthermore, we avoided preselection by including patients who, because of their clinical status, did not receive treatment of the ruptured aneurysm. Numerous studies have reported reasonable outcomes for elderly aSAH patients, but poor-grade patients are often underrepresented in these analyses [5] [6] [7] [8] [10] [11] [12] [13] [14] [15] although decision-making is the most challenging for this subgroup. Most studies measure outcome at discharge 9 and 2 to 4 months 7, 18 or 6 to 12 months 6,8,11,13,14 after aSAH. The additional survival analysis in this study provides new data beyond this usual follow-up period and illustrates how long-term survival is affected by poor-grade aSAH in elderly patients. Older age, poor-grade admission status, and ICH were identified as predictors for unfavorable outcome, which is consistent with other studies. 6, 7, 11, 13, 14 Some studies have reported more optimistic mortality rates and outcome parameters, mainly because they mixed good-grade and poor-grade elderly patients 7, 8, 14 or because WFNS V patients were excluded from the analysis.
11
Studies that assessed outcome separately for good-grade and poor-grade patients report similar results to our findings. 6, 9, 13 However, comparability between studies is limited if different outcome parameters were used and favorable and unfavorable outcomes were dichotomized differently.
Few studies have suggested age older than 75 years as being predictive of unfavorable outcomes.
11,13 Although poor-grade aSAH in elderly patients is associated with high mortality rates and unfavorable outcomes, the treatment of this subgroup seems reasonable. In the present study, 41.4% of patients in the age group 60 to 69 years, 17.6% of patients aged 70 to 79 years, and 10% of patients aged 80 to 90 years had favorable outcomes 6 to 12 months after aSAH, leading to a number needed to treat of 2.4 (60-69 years), 5.7 (70-79 years), and 10 (80-90 years) patients, respectively.
When comparing outcome at discharge and 6 to 12 months after aSAH, patients who were severely disabled at discharge (mRS score of 5) in the age groups 70 to 79 years and 80 to 90 years account for the most of the additional deaths after 6 to 12 months (mRS score of 6). This supports the assumption that older and more dependent patients have a poor prognosis even if they survived the acute phase of aSAH. By contrast, the younger group (aged 60-69 years) showed a greater potential for successful rehabilitation and favorable outcomes 6 to 12 months after aSAH, even if they were severely or moderately severely disabled at discharge. An important consideration in the controversial debate around treatment of elderly patients with poor-grade aSAH is the possibility of increasing the number of severely disabled and dependent patients. The results of this study show relatively low numbers of patients with severe and moderately severe disability 6 to 12 months after aSAH, indicating that offering treatment is reasonable.
The frequency of the decision not to treat an aneurysm differed significantly between age groups, and was most frequent for patients aged 80 to 90 years (80%), leading to a possible overestimation of mortality and unfavorable outcomes in this group. However, the frequency of withdrawal of care was slightly higher in older patients, although it did not reach statistical significance. To take into account a possible self-fulfilling prophecy (about survival and outcome in older patients and withdrawal of care), we repeated the statistical analysis excluding all patients who died because of the withdrawal of care (n=33). The reanalysis showed similar results to the original analysis with no changes about the significance except for OR for unfavorable outcome 6 to 12 months after aSAH (80-90 years compared with 60-69 years), which changed from P=0.02 to P=0.071. The detailed results of this analysis are provided in the online-only Data Supplement (Figures II and III and Tables I through III in 
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In a study by Nieuwkamp et al, 18 95% of poor-grade patients (57 out of 60) older than 75 years did not receive aneurysm treatment, which led to a mortality rate of 93%, and 7% severe disability, 2 to 4 months after aSAH. This mortality rate is most likely comparable to the age group 80 to 90 years in the present study, although we observed favorable outcomes in 10% of patients in this subgroup (mRS score of 3).
However, most of the poor-grade patients in the series studied by Nieuwkamp et al 18 were 75 to 79 years old. When comparing their results to those for the age group 70 to 79 years in our study, we found a lower mortality rate and a higher rate of favorable outcomes (17.6%), which is most likely related to the higher rate of aneurysm treatment in our cohort. In addition, preexisting medical conditions such as diabetes mellitus, arterial hypertension, and cerebrovascular disease increase with age in aSAH patients 7 and might play an important role in the prediction of outcome. The general health status of each individual patient should, therefore, be carefully considered when deciding if maximal treatment should be offered. Possible differences in the general health status complicate intergroup comparison, yet, to our understanding, this reflects the real-life situation.
Another important consideration when analyzing the outcome of aSAH patients in clinical studies is a potential misclassification of the admission WFNS score. 19 Low Glasgow coma scale values because of early sedation and relaxation can lead to an erroneous classification as poor-grade aSAH. The potential for good-grade aSAH patients to be misclassified as poor-grade patients can lead to inaccuracies of the power to predict outcome and in particular to an overestimation of favorable outcomes.
The definition of elderly in studies of aSAH patients varies widely and most authors consider patients older than 75 years as elderly. 12 Whereas it is accepted clinical practice to offer maximum treatment to young patients with poor-grade aSAH, maximum treatment of elderly patients with poorgrade aSAH remains a clinically challenging decision in each individual case. Therefore, the aim of this study was not to compare young to elderly poor-grade aSAH patients but rather to illustrate the continuous change of outcome and survival in patients at the end of their working lives (≥60 years).
The results of this study show an increasing risk for death and unfavorable outcome with increasing age in elderly patients with poor-grade aSAH. The mean survival time after aSAH decreased with age. Despite high initial mortality, a continuation of treatment resulted in favorable outcomes and a small proportion of patients who were moderately or severely disabled 6 to 12 months after aSAH in all groups. When comparing outcomes in the different age groups, a reasonable proportion of favorable outcomes 6 to 12 months after aSAH (41.4% and 17.6%; mostly mRS score of 0, 1, and 2) was observed in patients up to 79 years of age, whereas the proportion of patients with favorable outcomes was lowest in the age group 80 to 90 years (10%, only mRS score of 3) paired with a marked decrease in mean survival from 31.6±7.6 months (70-79 years) to 7.6±5.8 months (80-90 years). The quantitative evidence provided by this study is intended to support clinicians when making difficult decisions on treatment for elderly patients with poor-grade aSAH.
Limitations
Some limitations of the present study are acknowledged: The results of this study are subject to the well-known methodological limitations of retrospectively analyzed single-center cohorts. In addition, the pattern of referral of poor-grade aSAH patients to the neurosurgical center might have changed over the 12-year period, with a tendency to refer more poor-grade patients at the end of the study period than at the beginning, which might have led to selection bias about the cohort studied.
Conclusions
The risk for death increased by 6% per year of age and risk for unfavorable outcome by 11% per year of age in elderly patients with poor-grade aSAH. Despite high initial mortality, treatment resulted in a reasonable proportion of favorable outcomes up to 79 years of age and only a small number of patients who were moderately or severely 
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